Orchestra BioMed expects to receive up to $21 million in cash proceeds from the acquisition of Vivasure by Haemonetics.
$11 million of proceeds are expected in 2026 with the rest to be received in future revenue earnouts.
Vivasure's PerQseal Elite system offers a sutureless, fully absorbable solution for heart and endovascular procedures.
Proceeds Expectation
Orchestra BioMed anticipates receiving $11 million in 2026 and the remaining amount through future revenue earnouts.
PerQseal Elite Technology
Vivasure's PerQseal Elite system utilizes a proprietary bioabsorbable patch for large-bore arteriotomies and venotomies.
Leadership Statements
Leaders from Orchestra BioMed and Vivasure commend the strategic partnership and product development efforts.
Strategic Positioning
Haemonetics recognizes the clinical excellence of Vivasure's technology and the impact it brings to structural heart procedures.
Flagship Products
Orchestra BioMed's AVIM Therapy and Virtue SAB are in pivotal clinical trials with substantial market opportunities.
- The acquisition of Vivasure by Haemonetics brings a significant financial boost of up to $21 million to Orchestra BioMed.
- Vivasure's PerQseal Elite system's innovative technology for vessel closure strengthens Orchestra BioMed's product portfolio.
The acquisition marks a successful realization of long-term strategic partnerships for Orchestra BioMed, showcasing the company's commitment to innovative biomedical solutions.